Abstract
Introduction: In the phase III CheckMate 017 study, nivolumab prolonged overall survival versus docetaxel in previously treated patients with advanced squamous NSCLC. Study objectives included health-related quality of life (HRQoL) and symptom assessments. Methods: Patients serially completed the Lung Cancer Symptom Scale (LCSS) and European Quality of Life Five Dimensions (EQ-5D) questionnaires. The LCSS average symptom burden index (ASBI) (mean score for six lung cancer–specific symptoms; range 0–100), LCSS three-item global index, EQ-5D utility index, and EQ-5D visual analog scale scores were analyzed. The proportion of patients exhibiting clinically meaningful improvement (a ≥10-point decrease) in ASBI scores by week 12 was a secondary end point. Mixed-effect model repeated measures analysis of HRQoL changes from baseline and analyses of time to HRQoL deterioration were conducted. Results: Baseline mean plus or minus SD LCSS ASBI scores were similar in the nivolumab (29.6 ± 16.4) and docetaxel (29.6 ± 14.7) groups. By week 12, the proportions of patients (95% confidence interval) with clinically meaningful improvement in ASBI scores were 20.0% (13.6–27.7) with nivolumab and 21.9% (15.3–29.8) with docetaxel. At weeks 16 to 54, significant improvements in ASBI scores from baseline were seen with nivolumab; clinically meaningful improvements were observed at weeks 42 to 84. No significant changes in ASBI scores from baseline were observed with docetaxel; at week 36, a clinically meaningful deterioration was seen. Improvements in HRQoL with nivolumab versus with docetaxel were supported by other measures, and time to first HRQoL deterioration was longer. Conclusion: Nivolumab alleviates symptom burden and improves health status versus docetaxel as second-line squamous NSCLC treatment.
Original language | English (US) |
---|---|
Pages (from-to) | 194-204 |
Number of pages | 11 |
Journal | Journal of Thoracic Oncology |
Volume | 13 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2018 |
Keywords
- Advanced non–small cell lung cancer
- Docetaxel
- Health-related quality of life
- Nivolumab
- Symptom burden
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine